Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ: VKTX )

25.79 UNCHANGED
Streaming Delayed Price Updated: 4:15 PM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
9 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?
The weight-loss drugs space continues to heat up. Here's the latest news from the segment. 
Via Investor's Business Daily
Prediction: These Could Be the Best-Performing Pharma and Biotech Stocks Through 2030
Via The Motley Fool
2 Soaring Stocks That Could Climb 68% to 166% Higher in 2025, According to Wall Street
Via The Motley Fool
How Is The Market Feeling About Viking Therapeutics?
Via Benzinga
Is It Too Late to Buy Viking Therapeutics Stock?
Via The Motley Fool
Market Whales and Their Recent Bets on VKTX Options
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Warning: This Skyrocketing Stock Has a Hidden Risk
Via The Motley Fool
Should You Forget Pfizer and Buy These Unstoppable Stocks Instead?
Via The Motley Fool
After Crashing 27% in the Past Month, Is Viking Therapeutics Stock a Bargain Buy Right Now?
Via The Motley Fool
2 Disruptive Growth Stocks With Room to Run
Via The Motley Fool
This Autodesk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
Viking Therapeutics Stock On Brink Of Death Cross As Weight Loss Hype Loses Momentum
Analysts are concerned about Viking's ability to compete in the lucrative obesity drug market, dominated by Eli Lilly and Novo Nordisk. 
Via Benzinga
Here's Yet Another Reason to Buy Viking Therapeutics Stock Like There's No Tomorrow
Via The Motley Fool
Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs
The Biden Administration's proposal expands Medicare and Medicaid coverage for anti-obesity drugs, cutting costs for millions while addressing the obesity crisis. 
Via Benzinga
Billionaire Ken Griffin Invested $93 Million of Citadel's Portfolio in a Stock That Could Rocket 105% Higher, According to a Wall Street Analyst
Via The Motley Fool
3 Monster Stocks in the Making
Via The Motley Fool
Weight-Loss Drugs Don't Seem To Impress RFK Jr. Should Eli Lilly, Novo Nordisk Investors Worry?
Robert F. Kennedy hasn't overtly commented on how he would handle GLP-1 drugs. But there are hints. 
Via Investor's Business Daily
Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs
Viking Therapeutics' Phase 2b results show VK2809's efficacy in treating NASH, with significant liver fat reductions, NASH resolution, and fibrosis improvement. 
Via Benzinga
Money In Motion: Top Picks To Power Your Portfolio Today
Top stocks set to dominate the market today. 
Via Talk Markets
3 Things You Need to Know if You Buy Viking Therapeutics Today
Via The Motley Fool
Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On.
Mergers and acquisitions could make a comeback with Trump headed back to Washington. 
Via The Motley Fool
Topics Government
Exposures Political
Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead?
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Did Viking Therapeutics Just Say "Checkmate" To Eli Lilly?
Viking Therapeutics just revealed a new plan that could make waves in the weight loss industry. 
Via The Motley Fool
Is Viking Therapeutics a Buy on the Dip?
Viking stock has slipped more than 20% from its peak. 
Via The Motley Fool
Stock Market Surges To Highs On Trump Election; Fed Cuts Rates, Palantir Soars: Weekly Review
A Fed rate cut and a slew of big earnings reports filled out a busy week. 
Via Investor's Business Daily
Topics Economy Government
Exposures Interest Rates Political
4 Reasons Why Buying Viking Therapeutics Stock Right Now Is a Smart Move
All signs are pointing toward its continued success. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.